A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer

Annals of Surgical Oncology

Volumn 15, Issue 12, 2008, Pages 3407-3414

  Lyons III, John M ^a   Anthony, Cathy T ^a   Thomson, Jessica L ^b   Woltering, Eugene A ^a,c  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b SOUTHERN REGIONAL RESEARCH CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOTOXIC AGENT; DOXORUBICIN; FIBRIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; REAGENT; THROMBIN; VINCRISTINE;

ANGIOGENESIS; ARTICLE; ASSAY; BREAST CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; RATING SCALE; TIME; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL ASSAY; BLOOD COAGULATION; BREAST NEOPLASMS; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FIBRIN; FLUOROURACIL; HUMANS; METHOTREXATE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; THROMBIN; VINCRISTINE;

EID: 58149306180     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-0145-2     Document Type: Article

References (28)

1. JT Jørgensen KV Nielsen B Ejlertsen 2007 Pharmacodiagnostics and targeted therapies-a rational approach for individualizing medical anticancer therapy in breast cancer Oncologist 12 397 405
2. SE Salmon 1984 This Week's Citation Classic Current Contents by ISI 46 16
3. Schrag D, Garewal HS, Burstein HJ, et al. ASCO Working Group on Chemotherapy Sensitivity and Resistance Assays. American society of clinical oncology technology assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 2004;22:3631-8. Epub 2004 Aug 2
4. DJ Samson J Seidenfeld K Ziegler 2004 Chemotherapy sensitivity and resistance assays: a systematic review J Clin Oncol 22 3618 30
5. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-206
6. EA Woltering JM Lewis PJ Maxwell IV 2003 Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs Ann Surg 237 790 8
7. SA Gulec EA Woltering 2004 A new in vitro assay for human tumor angiogenesis: three-dimensional human tumor angiogenesis assay Ann Surg Oncol 11 99 104
8. JC Watson JG Redmmann MO Meyers 1997 Breast cancer increases initiation of angiogenesis without accelerating neovessel growth rate Surgery 122 509 14
9. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 717
10. S Boyd 1900 On oophorectomy in cancer of the breast Br Med J 2 1161 7
11. EV Jensen VC Jordan 2003 The estrogen receptor: a model for molecular medicine Clin Cancer Res 9 1980 9
12. C Shih LC Padhy M Murray 1981 Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts Nature 290 261 4
13. DJ Slamon GM Clark SG Wong 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 82
14. T Akiyama C Sudo H Ogawara 1986 The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity Science 232 1644 6
15. R Seshadri FA Firgaira DJ Horsfall 1993 Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group J Clin Oncol 11 1936 42
16. CL Vogel MA Cobleigh D Tripathy 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 26
17. AW Hamburger SE Salmon 1977 Primary bioassay of human tumor stem cells Science 197 461 3
18. DD Von Hoff GM Clark BJ Stogdill 1983 Prospective clinical trial of a human tumor cloning system Cancer Res 43 1926 31
19. JM Xu ST Song ZM Tang 1999 Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro Breast Cancer Res Treat 53 77 85
20. JU Maenpaa E Heinonen SM Hinkka 1995 The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial Gynecol Oncol 57 294 8
21. CM Kurbacher IA Cree HW Bruckner 1998 Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer Anti-cancer Drugs 9 51 7
22. DD Von Hoff JF Sandbach GM Clark 1990 Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician J Natl Cancer Inst 82 110 6
23. DH Kern LM Weisenthal 1990 Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures J Natl Cancer Inst 82 582 8
24. RS Mehta R Bornstein IR Yu 2001 Breast cancer survival and in vitro tumor response in the extreme drug resistance assay Breast Cancer Res Treat 66 225 37
25. G Bocci KC Nicolaou RS Kerbel 2002 Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs Cancer Res 62 6938 43
26. M Iwahana N Utoguchi T Mayumi 1998 Drug resistance and P-glycoprotein expression in endothelial cells of newly formed capillaries induced by tumors Anticancer Res 18 2977 80
27. M Cwikiel J Eskilsson M Albertsson 1996 The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture Ann Oncol 7 731 7
28. ME Maragoudakis P Peristeris E Missirlis 1994 Inhibition of angiogenesis by anthracyclines and titanocene dichloride Ann N Y Acad Sci 732 280 93